MERCK KGAA O.N.
Commented by Nico Popp on May 13th, 2025 | 07:10 CEST
The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma
Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.
Read
Commented by Stefan Feulner on April 28th, 2025 | 11:20 CEST
BioNTech, BioNxt, Merck KGaA – Opportunities after the correction
The reporting season for the first quarter of 2025 is underway, and due to US President Donald Trump's tariff hammer, it is more exciting than ever. Investors are likely to focus primarily on forecasts for the rest of the fiscal year. Internet giant Google posted impressive figures last week and is standing firm against looming trade conflicts and antitrust proceedings. Several companies in the biotech sector also had news to report and offer attractive entry opportunities at reduced prices.
Read
Commented by Stefan Feulner on July 30th, 2024 | 06:30 CEST
Viking Therapeutics, Vidac Pharma, Merck KGaA - In the footsteps of Novo Nordisk
Drugs for the treatment of diabetes and obesity have helped the pharmaceuticals manufacturer Novo Nordisk to become the most valuable listed company in Europe. But the competition is not sleeping. Many promising biotechs are already presenting new preparations that could overtake the Danes in the long term. Young companies with the chance of the next blockbuster also have great potential in other areas, such as cancer research.
Read
Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET
Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech
The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.
Read
Commented by Juliane Zielonka on April 14th, 2023 | 10:23 CEST
Bayer, Defence Therapeutics, Merck KGaA - Data power ensures high-speed commercialization
Germany is one of the best-funded countries in terms of research-based pharmaceutical companies. Nevertheless, Stefan Oelrich of Bayer Healthcare is critical. He thinks that data protection is putting the brakes on research. Defence Therapeutics, on the other hand, relies on enormous speed. Thanks to their data-driven ACCUM™ platform technology, they are helping mRNA vaccines, in particular, to achieve more intensive results. Pharmaceutical giant Merck is currently experiencing just how valuable data is in the US. In a Phase III clinical trial, the FDA stopped the enrolment of further patients, thus slowing down the research. The reason for the stop, however, is a serious one...
Read
Commented by Stefan Feulner on March 4th, 2022 | 13:33 CET
Bayer, Defence Therapeutics, Merck KGaA - At the start of the trend
The biotech industry is the innovative engine for a pharmaceutical industry dependent on new concepts due to the shift from blockbuster products to personalized medicine. Even before Corona, more than EUR seven billion per year was invested in R&D in 2019. The development of new drugs is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs is expiring or has already expired. For this reason, the pharmaceutical industry is now much more often entering biotech companies in the early development phases of a new drug. The example of vaccine manufacturers has successfully highlighted this strategy, which will also be applied to other diseases in the future.
Read
Commented by Carsten Mainitz on December 9th, 2021 | 04:57 CET
Barrick Gold, Barsele Minerals, Merck KGaA - Much movement in the market
Currently, there is little movement in the gold market. The gold price peaked at around USD 2,070 an ounce in the summer of last year, and it is now consolidating around USD 1,800. Investors prefer to invest in higher-yielding assets such as equities or cryptocurrencies despite the economic environment with high inflation and historically low-interest rates. Behind the scenes, however, a lot is going on in the gold market. Most recently, for example, Tembo Gold announced its entry by Barrick Gold, with further acquisitions to follow.
Read
Commented by Stefan Feulner on November 5th, 2021 | 11:22 CET
BioNTech, Sativa Wellness, Merck KGaA - Impressive trend
There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.
Read
Commented by Stefan Feulner on September 21st, 2021 | 13:21 CEST
Newmont, Triumph Gold, Merck KGaA, Fresnillo - Proven crisis protection
Following a historic reform, the DAX leading index now includes 40 companies to present the German economy comprehensively. In addition to the Franco-German aircraft manufacturer Airbus, companies such as the cooking box supplier HelloFresh, Porsche, and the online fashion retailer Zalando will play in the Champions League. The start was bumpy, which was not due to the composition but rather to the looming crisis in China, triggered by the Chinese real estate group Evergrande. Investors are fleeing equities and investing in gold in turbulent times. Historically, this scenario has proven itself many times. But gold is currently also in correction mode! In the long term, hardly anything goes past the precious yellow metal.
Read
Commented by Stefan Feulner on September 13th, 2021 | 13:43 CEST
Xiaomi, Troilus Gold, Merck - First-class developments
Substantial gains were recently seen in consumer and producer prices in Germany and Europe. Inflation in Germany reached its highest level in almost 28 years in August and is close to breaking through the 4% mark. In contrast to central banks, which consider the rate of inflation to be temporary and continue to maintain an ultra-loose monetary policy with interest rates at zero percent, economists expect inflation to remain permanently high. There is a threat of a decline in the value of money, which could be slowed down by buying gold. Currently, the precious metal is still trading at a favorable level.
Read